The representation displayed is that of cyclin-dependent kinase 2 (CDK2) as the protein. The ligand pictured is the , 4-(5-bromo-2-oxo-2h-indol-3-ylazo)- benzenesulfonamide. CDK2 is part of the Ser/Thr protein kinases. CDK2 is a positive regulator of the eukaryotic cell cycle progression and is a catalytic unit that helps the cell progress from the G1 phase to the S phase.
In the study “The Structure of Cyclin-Dependent Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor,” researchers studied whether using a topical oxindole inhibitor would reduce the chemotherapy-induced alopecia (CIA). Alopecia is characterized by hair loss. By inhibiting the CDK2, the cell cycle is slowed and the sensitivity to the epithelium from many cell cycle-active antitumor agents is reduced. Thus, a reduction in hair loss can be possible.
The oxindole inhibitor interacts with the CDK2 through a small .
The CDK2 is composed of a total of 7 alpha-helices and 6 beta-sheets. The can be seen here.
This presentation of the protein-ligand module shows the in which the oxindole inhibitor interacts with CDK2.
The oxindole inhibitor interacts with in a Pi-Pi, Pi-cation interaction. An interaction between the oxindole inhibitor and can be seen here in a hydrophobic interaction. Also, there are two sets of important hydrogen bonds between the oxindole inhibitor and CDK2: and .